Daré Bioscience, Inc., a biopharmaceutical company focused on women’s health therapeutics, announced that its corporate presentation delivered at the H.C. Wainwright 26th Annual Global Investment Conference is now accessible on-demand through the company’s investor relations portal.
The presentation, led by President and Chief Executive Officer Sabrina Martucci Johnson, provided an overview of Daré’s clinical development portfolio, commercialization strategies, and strategic partnerships. The discussion detailed ongoing initiatives for FDA-approved products, including XACIATO for the treatment of bacterial vaginosis, as well as pipeline candidates addressing female sexual arousal disorder and hormone replacement therapy.
The webcast features corporate updates on key clinical milestones, formulation technologies, and commercial collaboration agreements with global healthcare partners.
Interested stakeholders, analysts, and institutional investors can access the archived webcast presentation and accompanying slide deck on the investor relations section of Daré's official website, where the recording will remain available for 90 days following the conference.
